 |
|
TARKINAID, an international consortium of 11 class-leading academic and industrial research organisations from Europe and Brazil, kicked off to a €4 million research project to develop new ways of treating chronic autoimmune diseases such as rheumatoid arthritis.
The goal of the four-year project is to develop a novel class of drug candidates that can efficiently treat animal models of chronic autoimmune diseases and can enter clinical testing towards the end of the four-year project period. The total budget of the project is €4 million, €3 million of which is provided by the 7th Framework Programme of the European Union.
The consortium comprises a team of five highly competitive European universities and research institutions and two top Brazilian groups. The project is reinforced by three biotech companies for promoting translational research and a company managing EU-funded research projects. TARKINAID is anticipated to strengthen ties between the EU and Brazil, one of the World's largest emerging economies with significant expertise in testing animal models of inflammatory diseases. TARKINAID Participants: Semmelweis University, Budapest, Hungary (Coordinator) Ludwig-Maximilians Universität München, Germany Università degli Studi di Verona, Italy Centre National de la Recherche Scientifique, Toulouse, France Vichem Chemie Research Ltd., Budapest, Hungary Universitätsklinikum Freiburg, Germany Universidade Federal do Rio de Janeiro, Brazil Biomedcode Hellas SA, Athens, Greece Ambiotis SAS, Toulouse, France Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil ALTA Ricerca e Sviluppo in Biotecnologie S.r.l.u., Siena, Italy |
News
|
|
Biomedcode is a participant of the TheRAlead proposal, submitted under GSRT's (Greek General Secretariat of Research and Technology) SYNERGASIA action. The program will be funded with 1.8 million euros over the next 4 years.
TheRAlead aims to bridge the gap between target identification and pre-clinical validation exploiting a “hit to lead” pipeline, by integrating state-of-the-art tools and expertise of academic and industrial partners to address the development of novel therapeutic compounds for rheumatoid arthritis. The project will exploit an interdisciplinary approach consisting of structure based drug design, organic synthesis, in vitro screening, cellular assays, in silico optimisation, and validation in animal models of arthritis (a key task of Biomedcode). TheRAlead will capitalize on the scientific and technological excellence of its partners - two research institutes (The Coordinator BSRC Fleming and CERETETH), a university (Agricultural University of Athens), an SME (Biomedcode) and a pharmaceutical company (Pharmathen) - linked together by their joint interest in drug discovery and development. The Consortium aims to promote intense collaborative research and exchange of know-how to complete a successful drug discovery process for Rheumatoid Arthritis including early drug development stages, that is expected to yield several commercial opportunities for exploitation of results. |
|
|
AVESTHAGEN announced that it has successfully completed the pre-Clinical efficacy trial for one of its biosimilar drugs AVENT™ at Biomedcode Hellas S.A. AVENT™ is the biosimilar version of a fully humanized soluble tumor necrosis factor (TNF) receptor. The results indicate that AVENT™ developed by Avesthagen is effective in addressing arthritic conditions in the human TNF Tg197 mouse model of arthritis. The global sales of the commercially available reference drug were around $ 6.58 billion in 2009. AVENT™ is indicated for reducing signs and symptoms, in patients with moderate to severe Rheumatoid Arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and Juvenile Idiopathic Arthritis. |
 |
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the human TNF Tg197 gold standard transgenic mouse model for arthritis. Pre-clinical testing of this compound was conducted by BioMedCode, a recognized leader in the use of this transgenic model. |
 |
|